Seroatlas · Human Serome Atlas

BCL7A

B-cell CLL/lymphoma 7 protein family member A

Also known as: BCL7, BCL7A_HUMAN, SMARCJ1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q4VC05
Gene: BCL7A
Ensembl: ENSG00000110987
Chromosome: 12
Canonical length: 210 aa
Protein class: Cancer-related genes, Disease related genes, Predicted intracellular proteins
Subcellular location: Nucleoplasm,Vesicles

OverviewNCBI Gene

This gene is directly involved, with Myc and IgH, in a three-way gene translocation in a Burkitt lymphoma cell line. As a result of the gene translocation, the N-terminal region of the gene product is disrupted, which is thought to be related to the pathogenesis of a subset of high-grade B cell non-Hodgkin lymphoma. The N-terminal segment involved in the translocation includes the region that shares a strong sequence similarity with those of BCL7B and BCL7C. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

210 residues, UniProt reviewed canonical sequence.

>Q4VC05|BCL7A
     1  MSGRSVRAET RSRAKDDIKR VMAAIEKVRK WEKKWVTVGD TSLRIYKWVP VTEPKVDDKN
    61  KNKKKGKDEK CGSEVTTPEN SSSPGMMDMH DDNSNQSSIA DASPIKQENS SNSSPAPEPN
   121  SAVPSDGTEA KVDEAQADGK EHPGAEDASD EQNSQSSMEH SMNSSEKVDR QPSGDSGLAA
   181  ETSAISQDLE GVPPSKKMKL EASQQNSEEM

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against BCL7A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.68
Highest tissue expression: 23 nTPM

Expression across tissuesHPA

Tissue

thymus: 23 nTPM
cerebellum: 18 nTPM
cerebral cortex: 15 nTPM
lymph node: 15 nTPM
tonsil: 14 nTPM
kidney: 13 nTPM

Single-cell type

loop of henle epithelial cells: 82 nCPM
distal convoluted tubule cells: 79 nCPM
renal connecting tubule cells: 77 nCPM
renal collecting duct intercalated cells: 70 nCPM
proximal tubule cells: 64 nCPM
pdcs: 63 nCPM

Immune cell

plasmacytoid DC: 2.8 nTPM
naive B-cell: 2.1 nTPM
memory B-cell: 1 nTPM
myeloid DC: 0.3 nTPM
basophil: 0.1 nTPM
memory CD4 T-cell: 0.1 nTPM

Brain region

cerebral cortex: 29 nTPM
basal ganglia: 25 nTPM
white matter: 25 nTPM
cerebellum: 25 nTPM
hippocampal formation: 21 nTPM
amygdala: 19 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.73
gnomAD pLI: 0.08
gnomAD missense Z: 0.9
DepMap mean gene effect: -0.13
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads BCL7A as an antibody target. Whether an autoantibody or antibody against BCL7A could matter depends on whether native BCL7A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

BCL7A is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label BCL7A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...